1.
Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for
Study
1.2.3. Key Market
Segmentations
2.
Research Methodology
2.1.
Objective of the Study
2.2.
Baseline Methodology
2.3.
Key Industry Partners
2.4.
Major Association and Secondary Sources
2.5.
Forecasting Methodology
2.6.
Data Triangulation & Validation
2.7.
Assumptions and Limitations
3.
Executive Summary
3.1. Overview of the
Market
3.2. Overview of Key
Market Segmentations
3.3. Overview of Key
Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market
Drivers, Challenges, Trends
4.
Voice of Customer
5.
Clinical Trials Analysis
5.1.
Ongoing Clinical Trials
5.2.
Completed Clinical Trials
5.3.
Terminated Clinical Trials
5.4.
Breakdown of Pipeline, By Development Phase
5.5.
Breakdown of Pipeline, By Status
5.6.
Breakdown of Pipeline, By Study Type
5.7.
Breakdown of Pipeline, By Region
5.8.
Clinical Trials Heat Map
6. Global Cancer
Vaccine Market Outlook
6.1.
Market Size & Forecast
6.1.1. By Value
6.2.
Market Share & Forecast
6.2.1. By Indication Type (Prostate Cancer, Melanoma, Bladder Cancer, Cervical
Cancer
6.2.2. By Vaccine Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines)
6.2.3. By Technology Type (Recombinant Cancer Vaccines, Whole-Cell Cancer
Vaccines, Viral Vector and DNA Cancer Vaccines)
6.2.4. By Company (2022)
6.2.5. By Region
6.3.
Market Map
7. North America Cancer Vaccine Market Outlook
7.1.
Market Size & Forecast
7.1.1. By Value
7.2.
Market Share & Forecast
7.2.1.
By Indication Type
7.2.2.
By Vaccine Type
7.2.3.
By Technology Type
7.2.4. By Country
7.3.
North America: Country Analysis
7.3.1. United States Cancer
Vaccine Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Indication Type
7.3.1.2.2.
By Vaccine Type
7.3.1.2.3.
By Technology Type
7.3.2. Mexico Cancer
Vaccine Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Indication Type
7.3.2.2.2.
By Vaccine Type
7.3.2.2.3.
By Technology Type
7.3.3. Canada Cancer
Vaccine Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Indication Type
7.3.3.2.2.
By Vaccine Type
7.3.3.2.3.
By Technology Type
8. Europe Cancer Vaccine Market Outlook
8.1.
Market Size & Forecast
8.1.1. By Value
8.2.
Market Share & Forecast
8.2.1. By Indication Type
8.2.2. By Vaccine Type
8.2.3. By Technology Type
8.2.4. By Country
8.3.
Europe: Country Analysis
8.3.1. France Cancer Vaccine Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Indication Type
8.3.1.2.2.
By Vaccine Type
8.3.1.2.3.
By Technology Type
8.3.2. Germany Cancer
Vaccine Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Indication Type
8.3.2.2.2.
By Vaccine Type
8.3.2.2.3.
By Technology Type
8.3.3. United Kingdom Cancer
Vaccine Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Indication Type
8.3.3.2.2.
By Vaccine Type
8.3.3.2.3.
By Technology Type
8.3.4. Italy Cancer Vaccine
Market Outlook
8.3.4.1.
Market Size & Forecast
8.3.4.1.1.
By Value
8.3.4.2.
Market Share & Forecast
8.3.4.2.1.
By Indication Type
8.3.4.2.2.
By Vaccine Type
8.3.4.2.3.
By Technology Type
8.3.5. Spain Cancer Vaccine
Market Outlook
8.3.5.1.
Market Size & Forecast
8.3.5.1.1.
By Value
8.3.5.2.
Market Share & Forecast
8.3.5.2.1.
By Indication Type
8.3.5.2.2.
By Vaccine Type
8.3.5.2.3.
By Technology Type
9. Asia-Pacific Cancer Vaccine Market Outlook
9.1.
Market Size & Forecast
9.1.1. By Value
9.2.
Market Share & Forecast
9.2.1. By Indication Type
9.2.2. By Vaccine Type
9.2.3. By Technology Type
9.2.4. By Country
9.3.
Asia-Pacific: Country Analysis
9.3.1. China Cancer Vaccine
Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Indication Type
9.3.1.2.2.
By Vaccine Type
9.3.1.2.3.
By Technology Type
9.3.2. India Cancer Vaccine
Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Indication Type
9.3.2.2.2.
By Vaccine Type
9.3.2.2.3.
By Technology Type
9.3.3. South Korea Cancer
Vaccine Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Indication Type
9.3.3.2.2.
By Vaccine Type
9.3.3.2.3.
By Technology Type
9.3.4. Japan Cancer Vaccine
Market Outlook
9.3.4.1.
Market Size & Forecast
9.3.4.1.1.
By Value
9.3.4.2.
Market Share & Forecast
9.3.4.2.1.
By Indication Type
9.3.4.2.2.
By Vaccine Type
9.3.4.2.3.
By Technology Type
9.3.5. Australia Cancer
Vaccine Market Outlook
9.3.5.1.
Market Size & Forecast
9.3.5.1.1.
By Value
9.3.5.2.
Market Share & Forecast
9.3.5.2.1.
By Indication Type
9.3.5.2.2.
By Vaccine Type
9.3.5.2.3.
By Technology Type
10. South America Cancer
Vaccine Market Outlook
10.1. Market Size &
Forecast
10.1.1. By Value
10.2. Market Share &
Forecast
10.2.1. By Indication Type
10.2.2. By Vaccine Type
10.2.3. By Technology Type
10.2.4. By Country
10.3. South America:
Country Analysis
10.3.1. Brazil Cancer
Vaccine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1.
By Indication Type
10.3.1.2.2.
By Vaccine Type
10.3.1.2.3.
By Technology Type
10.3.2. Argentina Cancer
Vaccine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1.
By Indication Type
10.3.2.2.2.
By Vaccine Type
10.3.2.2.3.
By Technology Type
10.3.3. Colombia Cancer
Vaccine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1.
By Indication Type
10.3.3.2.2.
By Vaccine Type
10.3.3.2.3.
By Technology Type
11. Middle East and
Africa Cancer Vaccine Market Outlook
11.1. Market Size &
Forecast
11.1.1. By Value
11.2. Market Share &
Forecast
11.2.1. By Indication Type
11.2.2. By Vaccine Type
11.2.3. By Technology Type
11.2.4. By Country
11.3. MEA: Country
Analysis
11.3.1. South Africa Cancer
Vaccine Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1.
By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1.
By Indication Type
11.3.1.2.2.
By Vaccine Type
11.3.1.2.3.
By Technology Type
11.3.2. Saudi Arabia Cancer
Vaccine Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1.
By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1.
By Indication Type
11.3.2.2.2.
By Vaccine Type
11.3.2.2.3.
By Technology Type
11.3.3. UAE Cancer Vaccine Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1.
By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1.
By Indication Type
11.3.3.2.2.
By Vaccine Type
11.3.3.2.3.
By Technology Type
12.
Market Dynamics
12.1. Drivers
12.2. Challenges
13.
Market Trends & Developments
13.1. Recent Developments
13.2. Product Launches
13.3. Mergers &
Acquisitions
14.
PESTLE Analysis
15. Porter’s Five Forces
Analysis
15.1. Competition in the
Industry
15.2. Potential of New
Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute
Product
16.
Competitive Landscape
16.1. Business Overview
16.2. Company Snapshot
16.3. Products &
Services
16.4. Financials (In case
of listed companies)
16.5. Recent Developments
16.6. SWOT Analysis
16.6.1. Merck & Co.,
Inc.
16.6.2. GSK plc
16.6.3. Dendreon
Pharmaceuticals LLC.
16.6.4. Dynavax
Technologies.
16.6.5. Ferring B.V.
16.6.6. Amgen, Inc.
16.6.7. Moderna, Inc.
16.6.8. Sanofi SA
16.6.9. AstraZeneca
Pharmaceuticals LP
16.6.10. Bristol-Myers Squibb Company
17. Strategic Recommendations
18. About us & Disclaimer